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The original version of this article included the following
paragraph (p. 1161), which was incorrect:
"The manufacturer of the drug product was Onyx
Scientific Limited UK, to cGMP standards. Onyx
Scientific Limited UK also undertook the pharmaceuti-
cal form development work to establish the optimal pro-
cess for the manufacturer of the three doses of LSD.
The doses were made by the pharmacy at the clinical
trial facility under their manufacturing licence conditions
and following the process outlined in the IMPD. A
manual containing detailed instructions for the storage,
manufacture of the doses, dispensing, and reconciliation
was followed and worksheets were monitored by an
independent clinical research associate during the study.
LSD tartrate was prepared as a solution in distilled wa-
ter. Placebo was distilled water only (indistinguishable
from the LSD solution). Stability testing was done for a
6-month period."
The correct paragraph is presented here:
"The manufacturer of the drug product was Onyx Scientific
Limited UK, to cGMP standards. The doses were made by the
pharmacy at the clinical trial facility under their manufactur-
ing licence conditions and following the process outlined in
the Investigational Medicinal Product Dossier (IMPD). A
manual containing detailed instructions for the storage, man-
ufacture of the doses, dispensing, and reconciliation was
followed and worksheets were monitored by an independent
clinical research associate during the study. D-Lysergic acid
diethylamide (D-LSD, HPLC purity > 99%) was dissolved in
ethanol at 25 mg/mL and prepared as a solution 50 μg or 2 μg
D-LSD/mL in distilled water and completed to a final volume
of 10 mL distilled water for oral administration. A shelf life of
78 hours was allocated to the doses, when stored in the defined
container closure at a temperature of 2–8 °C, with the start of
the expiry period being defined as the time of combining the
D-LSD with ethanol. Placebo was distilled water only (indis-
tinguishable from the LSD solution)."
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